Andreas Argyrides
Stock Analyst at Oppenheimer
(4.53)
# 286
Out of 4,993 analysts
112
Total ratings
53.06%
Success rate
26.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $13.80 | +110.14% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $18.22 | +81.12% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: Outperform | $6 → $8 | $3.47 | +130.55% | 1 | Sep 8, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $425.42 | +35.16% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.33 | +181.43% | 2 | Sep 5, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $77 | $77.44 | -0.57% | 1 | Sep 3, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $5.36 | +273.13% | 2 | Aug 15, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $34 → $13 | $12.58 | +3.34% | 2 | Aug 6, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $27.04 | +125.59% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $5.26 | +33.08% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.29 | +132.56% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $22.45 | -42.09% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $0.48 | +734.72% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $38.15 | +135.91% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.07 | +334.78% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $15.80 | -5.06% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $189.74 | -4.61% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $4.86 | +434.98% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $56.38 | +84.46% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $3.73 | +1,910.72% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.78 | +223.74% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.54 | +99.16% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $17.50 | +65.71% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.36 | +124.36% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.72 | +1,164.11% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.65 | +122.22% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.90 | +679.25% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.63 | +1,479.28% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $52.62 | +33.03% | 6 | Aug 1, 2023 |
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $13.80
Upside: +110.14%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $18.22
Upside: +81.12%
Savara
Sep 8, 2025
Maintains: Outperform
Price Target: $6 → $8
Current: $3.47
Upside: +130.55%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $425.42
Upside: +35.16%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.33
Upside: +181.43%
Monopar Therapeutics
Sep 3, 2025
Initiates: Outperform
Price Target: $77
Current: $77.44
Upside: -0.57%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.36
Upside: +273.13%
Dyne Therapeutics
Aug 6, 2025
Maintains: Outperform
Price Target: $34 → $13
Current: $12.58
Upside: +3.34%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $27.04
Upside: +125.59%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $5.26
Upside: +33.08%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.29
Upside: +132.56%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $22.45
Upside: -42.09%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.48
Upside: +734.72%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $38.15
Upside: +135.91%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.07
Upside: +334.78%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $15.80
Upside: -5.06%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $189.74
Upside: -4.61%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $4.86
Upside: +434.98%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $56.38
Upside: +84.46%
Jun 25, 2024
Initiates: Outperform
Price Target: $75
Current: $3.73
Upside: +1,910.72%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.78
Upside: +223.74%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.54
Upside: +99.16%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $17.50
Upside: +65.71%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.36
Upside: +124.36%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.72
Upside: +1,164.11%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.65
Upside: +122.22%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.90
Upside: +679.25%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.63
Upside: +1,479.28%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $52.62
Upside: +33.03%